reported the emergence of resistance to miconazole of C. albieans during prolonged therapy for urinary candidiasis; the strain was found to be similarly resistant to clotrimazole and econazole.
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Any factor which compromises cell-mediated immunity will favour the emergence of Candida albicans as a chronic pathogen. Thus, treatment with corticosteroids or cytotoxic drugs, malnourishment, iron deficiency and endocrinopathy (particularly defects of calcium metabolism) may predispose some patients to chronic candidiasis. Patients with inadequate numbers of circulating lymphocytes or phagocytes, as well as those with poor phagocyte function, are also at risk. Some authorities therefore reserve the diagnosis of chronic mucocutaneous candidiasis (CMC) for those patients with chronic candidiasis in whom the above predisposing factors have been excluded (J R Hobbs, 1978, personal communication) .
In vivo tests
Patients with CMC fail to produce an effective immune response to candida. Immunological investigation aims at pin-pointing this defect. Cell-mediated immunity (CMI) is classically assessed in vivo by observing at 48 hours the inflammatory response to intradermal challenge. The continuing problem has been to make the challenge realistic. Unfortunately, commercially available preparations of candida extract allow IS-20% nonresponders amongst normals who could be expected to possess specific CMI against candida. Some centres, therefore, produce their own extract and claim fewer nonresponding normals (J R Hobbs, 1978, personal communication) .
Most patients with CMC, as expected, show no response to intradermal challenge. However, a few do respond, raising intriguing immunological questions yet to be resolved. In vitro studies Lymphocyte-rich fractions are prepared by layering heparinized blood onto Ficoll-trisosil and centrifuging. Aliquots of cells are suspended in Eagle's minimum essential medium augmented with 25% plasma, either the patient's own or pooled normal human AB plasma. Triplicate samples of each are then incubated with various stimulants or 'mitogens'. Blast transformation and cell division is accepted as evidence of lymphocyte response. This is quantified by adding radioactively-labelled thymidine for the final 24 hours of incubation, after which the amount of cell-bound radioactivity reflects the proportion of cells which have divided. Mitogens are chosen to test the capacity of a patient's lymphocytes to respond to: (1) a nonspecific stimulus, e.g. phytohaemagglutinin (PHA); (2) a 'known' antigen, to which the patient perforce has been already exposed, e.g. purified protein derivatives (PPD) or candida immunogen; (3) a mixed pool of foreign lymphocytes (MLR).
Unstimulated cultures are used to measure 'background' cell division. Results are expressed as a 'transformation increment' of stimulated minus background, or as a 'transformation index' of stimulated divided by background. Results are not arithmetically comparable between laboratories.
The lymphocytes of patients with CMC usually transform normally, to (1), (2) and (3), thus showing that they have the capacity to recognize and divide in response to candida (despite their negative skin tests). Two patients have been reported whose lymphocytes, though responding normally when incubated with pooled AB plasma, responded subnormally in their own plasma. This and other experimental evidence. suggests that 'blocking factors' are responsible for inadequate immunity to candida in a small proportion of patients with CMC (H Valdimarsson, 1978, personal communication) .
Lymphokines
One way in which responding lymphocytes can mobilize inflammation is by the secretion of lymphokines, one of which, macrophage migration inhibition factor (MIF), is amenable to measurement. The ability of patients with CMC to produce MIF in specific response to candida can be measured as follows. Patient's lymphocytes are incubated in Eagle's minimum essential medium for three days with candida extract, and each day the supernatant is changed and saved for MIF assay. Macrophages, harvested from the peritoneal cavities of disease-free guinea pigs, are packed into capillary tubes and placed in special chambers. After 24 hours the rnacrophages will migrate from the tubes to cover an area which can be visualized with magnification and accurately measured (at the Westminster Hospital, with a computerlinked projection technique) (Byrom, Campbell & Staughton, unpublished) . If the capillary tubes are bathed in a sample containing MIF, the degree of inhibition of normal migration can be easily measured (Valdimarsson et al. 1972) .
Using this technique it has been shown that lymphocytes of some 50% of patients with CMC, whilst dividing in response to candida, fail to produce MIF. Thus the 'effector' arm of their cell-mediated immunity is inadequate. Valdimarsson and colleagues (1972) reported clinical improvement in such a patient after treatment with lymphocytes from his HLA compatible sibling; in this patient MIF production was shown to be restored by the transfusion. Other empirically successful immunological stimulants, such as levamisole and transfer factor, may exert their beneficial effect by augmenting lymphokine production in some way (Schulkind et al. 1972) .
